search

Active clinical trials for "Wet Macular Degeneration"

Results 1-10 of 229

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

This study is designed for multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injection of IBI333 in subjects with neovascular age-related macular degeneration (nAMD).

Recruiting21 enrollment criteria

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients...

Wet Macular DegenerationNeovascular Age-related Macular Degeneration1 more

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Recruiting12 enrollment criteria

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related...

Neovascular Age-related Macular Degeneration

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.

Recruiting12 enrollment criteria

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Neovascular Age-Related Macular Degeneration

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Recruiting64 enrollment criteria

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Exudative Macular Degeneration

The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).

Recruiting21 enrollment criteria

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Recruiting6 enrollment criteria

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Neovascular Age-related Macular DegenerationDiabetic Macular Edema1 more

Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).

Recruiting20 enrollment criteria

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular...

Neovascular Age-related Macular Degeneration

Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

Recruiting16 enrollment criteria

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked...

Neovascular Age-related Macular Degeneration (NVAMD)Diabetic Macular Edema (DME)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Recruiting9 enrollment criteria

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular...

Neovascular Age-related Macular Degeneration

This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).

Recruiting56 enrollment criteria
12...23

Need Help? Contact our team!


We'll reach out to this number within 24 hrs